Published in Ann Intern Med on December 15, 2009
Public health research: lost in translation or speaking the wrong language? Am J Public Health (2011) 1.24
The dynamics of risk perceptions and precautionary behavior in response to 2009 (H1N1) pandemic influenza. BMC Infect Dis (2010) 1.20
Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemics. PLoS One (2012) 1.11
Trends in parameterization, economics and host behaviour in influenza pandemic modelling: a review and reporting protocol. Emerg Themes Epidemiol (2013) 0.93
Simulating school closure policies for cost effective pandemic decision making. BMC Public Health (2012) 0.89
A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness. BMC Infect Dis (2014) 0.79
Cost-effectiveness of pneumococcal and influenza vaccination standing order programs. Am J Manag Care (2013) 0.79
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics. Br J Clin Pharmacol (2017) 0.75
Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage. F1000Res (2016) 0.75
Factors Influencing H1N1 Vaccination Among Primary Health Care Workers: A Cross-Sectional Study. Int J Prev Med (2013) 0.75
The modern crystal ball: influenza forecasting with mathematical models. Ann Intern Med (2009) 0.75
Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature (2005) 30.92
Strategies for mitigating an influenza pandemic. Nature (2006) 25.20
Containing pandemic influenza at the source. Science (2005) 23.95
Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A (2006) 17.88
Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med (2005) 15.53
Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med (2005) 14.59
Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA (1996) 14.23
Containing pandemic influenza with antiviral agents. Am J Epidemiol (2004) 12.82
1918 Influenza: the mother of all pandemics. Emerg Infect Dis (2006) 12.11
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med (2006) 9.73
Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med (2002) 9.47
Deaths: final data for 2005. Natl Vital Stat Rep (2008) 7.50
Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature (2004) 6.11
The effect of public health measures on the 1918 influenza pandemic in U.S. cities. Proc Natl Acad Sci U S A (2007) 5.73
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet (2006) 5.72
Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest (1998) 5.70
Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial. Ann Intern Med (2009) 5.68
Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med (2006) 5.14
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet (2007) 4.84
Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis (1999) 4.67
H5N1 influenza--continuing evolution and spread. N Engl J Med (2006) 4.47
The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making (1993) 4.46
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep (2009) 4.36
Global transmission of oseltamivir-resistant influenza. N Engl J Med (2009) 4.34
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet (2006) 4.22
Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med (2005) 4.22
Targeted social distancing design for pandemic influenza. Emerg Infect Dis (2006) 4.17
Transmission of infectious diseases during commercial air travel. Lancet (2005) 3.97
Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. Emerg Infect Dis (2006) 3.96
Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J Infect Dis (2000) 3.63
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med (2008) 3.28
Low frequency of poultry-to-human H5NI virus transmission, southern Cambodia, 2005. Emerg Infect Dis (2006) 2.98
Food markets with live birds as source of avian influenza. Emerg Infect Dis (2006) 2.55
Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis (1970) 2.53
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2002) 2.21
Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med (2008) 2.21
Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One (2008) 2.20
Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One (2008) 2.18
Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis (2009) 2.17
Vaccines for seasonal and pandemic influenza. J Infect Dis (2006) 2.14
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A (2009) 2.08
Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine (2003) 2.04
Emerging infectious diseases: public health issues for the 21st century. Science (1999) 2.03
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis (2008) 2.02
An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis (2008) 2.01
Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med (2009) 1.99
Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis (2008) 1.87
MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One (2009) 1.79
Simple models for containment of a pandemic. J R Soc Interface (2006) 1.78
"Prepandemic" immunization for novel influenza viruses, "swine flu" vaccine, Guillain-Barré syndrome, and the detection of rare severe adverse events. J Infect Dis (2009) 1.77
Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol (2007) 1.73
Quantifying the routes of transmission for pandemic influenza. Bull Math Biol (2008) 1.62
Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004. Emerg Infect Dis (2005) 1.58
Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother (2006) 1.51
Effective, robust design of community mitigation for pandemic influenza: a systematic examination of proposed US guidance. PLoS One (2008) 1.47
Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis (2006) 1.41
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine (2008) 1.40
The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol (2000) 1.38
Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology (2003) 1.37
Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine (2008) 1.35
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis (2008) 1.28
Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to avian influenza (H5N1) in a tertiary care center. Clin Infect Dis (2004) 1.26
Influenza A: infection and reinfection. J Hyg (Lond) (1984) 1.16
The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine (2005) 1.15
Reinfection with influenza A (H2N2, H3N2, and H1N1) viruses in soldiers and students in Japan. J Infect Dis (1986) 1.10
Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm (2009) 1.04
Vaccine preparedness--are we ready for the next influenza pandemic? N Engl J Med (2008) 1.03
H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes. J Virol Methods (2006) 1.01
A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol (2007) 0.95
The virulence of the 1918 pandemic influenza virus: unraveling the enigma. Arch Virol Suppl (2005) 0.90
Molecular epidemiology of influenza A(H3N2) virus reinfections. J Infect Dis (2002) 0.88
Cost analysis of post-polio certification immunization policies. Bull World Health Organ (2004) 0.87
Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS One (2008) 0.86
Reducing mortality from anthrax bioterrorism: strategies for stockpiling and dispensing medical and pharmaceutical supplies. Biosecur Bioterror (2006) 0.85
Mass smallpox vaccination and cardiac deaths, New York City, 1947. Emerg Infect Dis (2004) 0.84
[Comparative clinical trial of vaccines against avian influenza]. Zh Mikrobiol Epidemiol Immunobiol (2007) 0.78
Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med (2007) 9.88
Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA (2006) 9.36
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med (2005) 7.98
Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med (2005) 7.46
Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. Ann Intern Med (2010) 5.14
Systematic review: surveillance systems for early detection of bioterrorism-related diseases. Ann Intern Med (2004) 4.58
Quality improvement strategies for hypertension management: a systematic review. Med Care (2006) 4.29
Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med (2008) 4.28
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16
Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med (2003) 3.88
Toward a 21st-century health care system: recommendations for health care reform. Ann Intern Med (2009) 3.85
Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine (Phila Pa 1976) (2009) 3.45
Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med (2007) 3.17
Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2007) 3.14
Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med (2007) 3.10
Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med (2007) 3.03
Systematic review: elective induction of labor versus expectant management of pregnancy. Ann Intern Med (2009) 3.01
Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med (2008) 2.96
Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med (2004) 2.89
Trends in inpatient treatment intensity among Medicare beneficiaries at the end of life. Health Serv Res (2004) 2.83
Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med (2006) 2.80
Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from theAmerican College of Physicians. Ann Intern Med (2014) 2.75
The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med (2010) 2.71
Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 2.69
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2007) 2.69
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med (2014) 2.69
Geographic variation in health care spending in the United States: insights from an Institute of Medicine report. JAMA (2013) 2.68
Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med (2011) 2.68
Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA (2006) 2.53
Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. Ann Intern Med (2006) 2.49
The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med (2012) 2.34
Diagnostic imaging for low back pain: advice for high-value health care from the American College of Physicians. Ann Intern Med (2011) 2.29
Technology diffusion, hospital variation, and racial disparities among elderly Medicare beneficiaries: 1989-2000. Med Care (2005) 2.26
Cost-effectiveness of elective induction of labor at 41 weeks in nulliparous women. Am J Obstet Gynecol (2010) 2.22
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med (2007) 2.16
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol (2007) 2.09
Influence of race on inpatient treatment intensity at the end of life. J Gen Intern Med (2007) 2.07
Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med (2013) 2.05
Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation (2010) 2.00
Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 1.98
Trends in implantable cardioverter-defibrillator racial disparity: the importance of geography. J Am Coll Cardiol (2005) 1.98
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
Consequences of health trends and medical innovation for the future elderly. Health Aff (Millwood) (2005) 1.95
Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 1.92
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90
A menu without prices. Ann Intern Med (2008) 1.89
Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 1.83
Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med (2008) 1.78
Evaluation of primary care patients with chronic stable angina: guidelines from the American College of Physicians. Ann Intern Med (2004) 1.78
The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med (2010) 1.76
Cost-effectiveness of helicopter versus ground emergency medical services for trauma scene transport in the United States. Ann Emerg Med (2013) 1.74
Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med (2007) 1.72
Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med (2005) 1.69
Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med (2009) 1.68
Transcatheter aortic valve replacement in nonsurgical candidates with severe, symptomatic aortic stenosis: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes (2013) 1.68
Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing. J Gen Intern Med (2008) 1.67
Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC Cardiovasc Interv (2008) 1.66
Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med (2008) 1.65
Essential elements of a technology and outcomes assessment initiative. JAMA (2007) 1.63
Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. Am J Med (2003) 1.63
Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med (2011) 1.62
Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med (2003) 1.61
Evidence-based medicine and policy: the case of the implantable cardioverter defibrillator. Health Aff (Millwood) (2005) 1.60
Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med (2007) 1.54
Geographic variation in Medicare services. N Engl J Med (2013) 1.51
Three large-scale changes to the Medicare program could curb its costs but also reduce enrollment. Health Aff (Millwood) (2013) 1.50
Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One (2013) 1.49
Maternal and neonatal outcomes of elective induction of labor. Evid Rep Technol Assess (Full Rep) (2009) 1.49
Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS (2006) 1.48
Racial disparity in cardiac procedures and mortality among long-term survivors of cardiac arrest. Circulation (2003) 1.45
Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2004) 1.45
Implementing effective hypertension quality improvement strategies: barriers and potential solutions. J Clin Hypertens (Greenwich) (2008) 1.44
Training synergies between medical informatics and health services research: successes and challenges. J Am Med Inform Assoc (2002) 1.42
Comparative effectiveness of HIV testing and treatment in highly endemic regions. Arch Intern Med (2010) 1.41
Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure. Ann Intern Med (2015) 1.39
The effect of geriatrics evaluation and management on nursing home use and health care costs: results from a randomized trial. Med Care (2006) 1.37
Simple counts of ADL dependencies do not adequately reflect older adults' preferences toward states of functional impairment. J Clin Epidemiol (2008) 1.37
Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med (2003) 1.33
Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2009) 1.30
Management of obstructive sleep apnea in adults: A clinical practice guideline from the American College of Physicians. Ann Intern Med (2013) 1.27
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making (2012) 1.24
Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med (2008) 1.23
Extracting subject demographic information from abstracts of randomized clinical trial reports. Stud Health Technol Inform (2007) 1.22
Cost-effectiveness analysis of nephron sparing options for the management of small renal masses. J Urol (2011) 1.21
Challenges in systematic reviews: synthesis of topics related to the delivery, organization, and financing of health care. Ann Intern Med (2005) 1.20
Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS (2011) 1.18
The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res (2006) 1.18